Therefore, these in vitro findings warrant further validation in vivo in animal models, as well as clinical investigation in patients with migraine, by taking advantage of the availability of various GSK-3β inhibitors currently ongoing clinical trials. The gene discussed is GSK3B; the disease is migraine disorder.